Lutetium Lu 177 dotatate: complete guide

Lutetium Lu 177 dotatate is a peptide-based radioligand therapy first approved by FDA as Lutathera in 2018. This guide covers its structure, mechanism, labeled use, trials and warnings.

Complete guide6 min read

Key takeaway

FDA first approved lutetium Lu 177 dotatate as Lutathera on January 26, 2018. A second brand, Bexlutry, was approved on September 14, 2026. In the NETTER-1 trial, the hazard ratio for progression or death was 0.21 versus octreotide alone.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Lutathera on January 26, 2018.” (this article)
ClassPeptide science
Studies cited3 in this article · 3 across 1 article on Lutetium Lu 177 dotatate
Related productsResearch peptide catalog

Lutetium Lu 177 dotatate is a radioactive cancer drug built on a small somatostatin-like peptide. The peptide carries the radioactive metal lutetium-177 to tumor cells that display somatostatin receptors. This guide covers its structure, mechanism, approvals, trials and label warnings, with sources checked on November 17, 2026.

Quick answer: Lutetium Lu 177 dotatate is a prescription radioligand therapy. Its labels cover somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors. Lutathera is approved for adults and children 12 and older; Bexlutry for adults. There is no boxed warning. Key warnings include radiation exposure, low blood counts, secondary blood cancers and kidney toxicity.

Vitrapep does not sell lutetium Lu 177 dotatate; this page is a reference summary of published research and regulatory information.

What is lutetium Lu 177 dotatate?

The molecule has three parts. A short peptide finds the tumor. A chelator, a cage-like molecule, holds a metal atom tightly. The metal is lutetium-177, a radioactive form of lutetium that damages nearby cells.

The Lutathera label states: “Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog.” It adds that the drug substance “is a cyclic peptide linked with the covalently bound chelator.” The label gives a molecular weight of 1,609.6 daltons (Lutathera label, 2024). Somatostatin is a natural hormone that slows the release of other hormones.

The peptide is dotatate, also called DOTA-Tyr3-octreotate. The NETSPOT label describes it as a cyclic peptide of 8 amino acids with the sequence H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH (NETSPOT label, 2023). PubChem lists the lutetium complex as C65H87LuN14O19S2 (PubChem CID 76966897). Our peptide primer explains why short amino acid chains like this count as peptides.

Drugs@FDA lists the original approval of Lutathera on January 26, 2018, under NDA 208700 (Drugs@FDA). Curium’s Bexlutry followed under NDA 218525 (Drugs@FDA).

Table 1

Lutetium Lu 177 dotatate: key facts

Fact Detail
Structure type Cyclic 8 amino acid peptide (Tyr3-octreotate) with a DOTA chelator holding lutetium-177
Class Radiolabeled somatostatin analog; radioligand therapy
Molecular formula C65H87LuN14O19S2 (PubChem)
Molecular weight 1,609.6 daltons (label); 1,609.5 g/mol (PubChem)
First FDA approval January 26, 2018 (Lutathera, NDA 208700)
Brand names (US) Lutathera (2018); Bexlutry (2026)

How does lutetium Lu 177 dotatate work?

It works like a guided delivery. The label states that it “binds to somatostatin receptors with highest affinity for subtype 2 somatostatin receptors (SSTR2).” Once bound, the lutetium-177 releases beta particles at close range.

The label explains the damage: “The beta-minus emission from lutetium-177 induces cellular damage by formation of free radicals” (Lutathera label, 2024). Free radicals are reactive molecules that injure DNA and other cell parts. The same peptide paired with gallium-68 becomes an imaging agent; see our gallium Ga 68 dotatate guide.

What is lutetium Lu 177 dotatate approved for?

Lutathera “is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).” The label adds that this includes “foregut, midgut, and hindgut neuroendocrine tumors” (Lutathera label, 2024). Drugs@FDA lists the pediatric expansion as a new patient population approval on April 23, 2024.

The Bexlutry label covers the same tumor type in adults only (Bexlutry label, 2026). Gastroenteropancreatic means arising in the stomach, intestines or pancreas.

What did the key trials show?

NETTER-1. This randomized, multicenter, open-label phase 3 trial enrolled 229 adults with well-differentiated, metastatic midgut neuroendocrine tumors. It compared lutetium Lu 177 dotatate plus octreotide with octreotide alone (NCT01578239). The primary end point was progression-free survival.

The estimated progression-free survival rate at month 20 was 65.2% with the drug and 10.8% in the control group. The response rate was 18% versus 3% (Strosberg et al., 2017). The label reports a hazard ratio of 0.21 for progression or death. At the final analysis, median overall survival was 48.0 months versus 36.3 months. That difference was not statistically significant (hazard ratio 0.84; p = 0.30) (Strosberg et al., 2021).

NETTER-2. This open-label phase 3 trial tested the drug as first treatment in newly diagnosed, advanced grade 2 or 3 gastroenteropancreatic tumors. It randomized 226 patients aged 15 or older. Median progression-free survival was 22.8 months with the drug plus octreotide and 8.5 months with octreotide alone. The stratified hazard ratio was 0.276 (p < 0.0001) (Singh et al., 2024; NCT03972488). All of these data come from human trials.

What side effects does the label list?

The Lutathera label has no boxed warning. In NETTER-1, the most frequent adverse reactions in the Lutathera arm included:

  • nausea (65%);
  • vomiting (53%);
  • fatigue (38%);
  • abdominal pain (26%);
  • diarrhea (26%); and
  • decreased appetite (21%).

The most common grade 3 or 4 reactions were lymphopenia, raised GGT, vomiting, nausea, raised liver enzymes, high blood sugar and low potassium. Lymphopenia, a drop in a type of white blood cell, reached grade 3 or 4 in 44%.

The warnings section covers radiation exposure, myelosuppression (low blood counts), secondary myelodysplastic syndrome and leukemia, kidney toxicity, liver toxicity and hypersensitivity. It also covers neuroendocrine hormonal crisis, harm to a fetus and infertility (Lutathera label, 2024). In long-term NETTER-1 follow-up, 2 of 111 patients (2%) developed myelodysplastic syndrome.

What is lutetium Lu 177 dotatate’s regulatory status, and how is it used in research?

Both brands are prescription drugs in the United States. Drugs@FDA lists Lutathera, held by Advanced Accelerator Applications USA, and Bexlutry, held by Curium, as prescription products. The Bexlutry label lists the same initial U.S. approval year as Lutathera, 2018.

Recent trials have tested the drug earlier in the disease course and in younger patients. NETTER-2 tested it as first treatment in higher-grade tumors. A study in adolescents, NETTER-P, supplied safety data from 9 pediatric patients for the label (NCT04711135). The label notes that pediatric efficacy is based on adult data.

Frequently asked questions about lutetium Lu 177 dotatate

Is lutetium Lu 177 dotatate a peptide?

Its targeting part is. Dotatate is a cyclic peptide of 8 amino acids joined to a DOTA chelator that holds lutetium-177.

When was Lutathera approved?

Drugs@FDA lists the original approval of Lutathera on January 26, 2018.

What is the difference between Lutathera and Bexlutry?

Both contain lutetium Lu 177 dotatate. Lutathera is labeled for adults and children 12 and older. Bexlutry, approved in September 2026, is labeled for adults.

Did it improve overall survival in NETTER-1?

No. Median overall survival was longer, 48.0 versus 36.3 months, but the difference was not statistically significant.

Does it have a boxed warning?

No. Its warnings include radiation exposure, low blood counts, secondary blood cancers, kidney and liver toxicity, and infertility.

What to know now

  • Structure: cyclic 8 amino acid peptide plus DOTA chelator plus lutetium-177.
  • Approval: Lutathera, January 26, 2018; Bexlutry, September 14, 2026.
  • Mechanism: binds SSTR2; beta emission damages cells through free radicals.
  • Label: somatostatin receptor positive GEP-NETs.
  • Evidence: progression hazard ratio 0.21 in NETTER-1 and 0.276 in NETTER-2.
  • Safety: no boxed warning; nausea and vomiting common; blood count and blood cancer warnings.

What we’re watching

Whether the Lutathera label adds NETTER-2 data; the October 2024 label we checked does not name that trial. NETTER-2 and NETTER-P are both listed as active, not recruiting, on ClinicalTrials.gov. Further revisions to the new Bexlutry label, approved September 14, 2026. Related guides: gallium Ga 68 dotatate, lutetium Lu 177 vipivotide tetraxetan and octreotide.

Sources: Advanced Accelerator Applications USA 2024, LUTATHERA (lutetium Lu 177 dotatate) prescribing information; Curium US LLC 2026, BEXLUTRY (lutetium Lu 177 dotatate) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 208700 (LUTATHERA) . Retrieved November 17, Drugs@FDA: NDA 208700 (LUTATHERA); U.S. Food and Drug Administration. Drugs@FDA: NDA 218525 (BEXLUTRY) . Retrieved November 17, Drugs@FDA: NDA 218525 (BEXLUTRY); Advanced Accelerator Applications USA 2023, NETSPOT (gallium Ga 68 dotatate) prescribing information; National Center for Biotechnology Information 2026, PubChem compound summary for CID 76966897, lutetium Lu 177 dotatate; Strosberg 2017, The New England Journal of Medicine, 376; Strosberg 2021, The Lancet Oncology, 22; Advanced Accelerator Applications 2012; Singh 2024, The Lancet, 403; Advanced Accelerator Applications 2019; Advanced Accelerator Applications 2021. All 12 citations

Back to the research library

References

  1. Advanced Accelerator Applications USA, Inc. (2024). LUTATHERA (lutetium Lu 177 dotatate) prescribing information (revised 10/2024). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72d1a024-00b7-418a-b36e-b2cb48f2ab55
  2. Curium US LLC. (2026). BEXLUTRY (lutetium Lu 177 dotatate) prescribing information (revised 9/2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7642094-9ec6-4927-8582-bbe60e5e74cc
  3. U.S. Food and Drug Administration. Drugs@FDA: NDA 208700 (LUTATHERA). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208700
  4. U.S. Food and Drug Administration. Drugs@FDA: NDA 218525 (BEXLUTRY). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218525
  5. Advanced Accelerator Applications USA, Inc. (2023). NETSPOT (gallium Ga 68 dotatate) prescribing information (revised 10/2023). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2b3be70-17d8-4093-896c-f1c54a2cf242
  6. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 76966897, lutetium Lu 177 dotatate. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/76966897
  7. Strosberg, J., et al. (2017). Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. The New England Journal of Medicine, 376(2), 125-135. https://doi.org/10.1056/NEJMoa1607427
  8. Strosberg, J. R., et al. (2021). 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. The Lancet Oncology, 22(12), 1752-1763. https://doi.org/10.1016/S1470-2045(21)00572-6
  9. Advanced Accelerator Applications. (2012). A study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive midgut carcinoid tumours (NETTER-1) (ClinicalTrials.gov ID NCT01578239). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT01578239
  10. Singh, S., et al. (2024). [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): An open-label, randomised, phase 3 study. The Lancet, 403(10446), 2807-2817. https://doi.org/10.1016/S0140-6736(24)00701-3
  11. Advanced Accelerator Applications. (2019). Study to evaluate the efficacy and safety of Lutathera in patients with grade 2 and grade 3 advanced GEP-NET (NETTER-2) (ClinicalTrials.gov ID NCT03972488). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT03972488
  12. Advanced Accelerator Applications. (2021). Study to evaluate safety and dosimetry of Lutathera in adolescent patients with GEP-NETs and PPGLs (NETTER-P) (ClinicalTrials.gov ID NCT04711135). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04711135